BioMarin Pharmaceutical | BMRN - Beneficio Bruto En Ventas

Precio De Mercado
54.21
Cambio Diario
0.91 1.71%
Mensual
-1.06%
Anual
-14.88%
Q2 Expectativa
52.04




Beneficio Bruto En Ventas Cambio Fecha
Acadia Pharmaceuticals USD 257.76M 778K 2025-12
Agios Pharmaceuticals USD 18.09M 6.89M 2025-12
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
Amgen USD 6.48B 307M 2025-09
Bayer EUR 5.35B 1.02B 2025-09
Biogen USD 1.65B 34.6M 2025-12
BioMarin Pharmaceutical USD 713.01M 81.81M 2025-12
Gilead Sciences USD 6.31B 106M 2025-12
Incyte USD 1.17B 217.51M 2026-03
Insmed USD 217.69M 106.25M 2025-12
Ionis Pharmaceuticals USD 243M 48M 2026-03
Moderna USD 226M 583M 2025-12
Neurocrine Biosciences USD 787.9M 7M 2025-12
PTC Therapeutics USD 148.38M 39.31M 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 3.3B 67M 2025-12
Roche Holding CHF 22.09B 10.04B 2025-12
Sangamo BioSciences -2.39M 1.09M 2024-06
Sanofi EUR 8.45B 3.02B 2025-12
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
United Therapeutics USD 315.5M 286.6M 2025-12
Vertex Pharmaceuticals USD 2.72B 62.4M 2025-12